Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Saved in:
| Title: | Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer. |
|---|---|
| Authors: | Solzak JP; Department of Surgery, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA., Atale RV; Department of Surgery, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA., Hancock BA; Department of Surgery, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA., Sinn AL; In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN USA., Pollok KE; In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN USA.; Herman B. Wells Center for Pediatric Research, Department of Pediatrics, Section of Pediatric Hematology/Oncology, Riley Hospital for Children at Indiana University Health Department of Pharmacology and Toxicology, Indianapolis, IN USA., Jones DR; Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN USA., Radovich M; Department of Surgery, Indiana University School of Medicine, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN USA. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2017 Apr 26; Vol. 3, pp. 17. Date of Electronic Publication: 2017 Apr 26 (Print Publication: 2017). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: eCollection Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
